Travere Therapeutics (TVTX) Tops Q4 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Travere Therapeutics (TVTX) PT Raised to $35 at Citi
February 24, 2025 4:58 AM ESTCiti analyst Carly Kenselaar raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $35.00 (from $31.00) while maintaining a Buy rating.
The analyst comments "We anticipate continued growth for FILSPARI in 2025, driven by 1) expected approval in FSGS in 4Q25 with an sNDA... More
